ClinicalThought
Considerations for Managing Advanced Urothelial Cancer With Novel Therapies
Release Date: January 4, 2022
Expiration Date: January 3, 2023
Not certified for credit.
Begin »
Program Overview
Program Description
The treatment landscape for advanced urothelial cancer is rapidly evolving and expanding. Identifying optimal therapies is key to optimizing patient outcomes. Read this commentary on important considerations for managing patients with advanced urothelial cancer using the most recent therapeutic advances available for these patients.
Format
Clinical Thought
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Arjun Balar, MD
- Associate Professor of Medicine
- Division of Hematology/Oncology
- NYU Langone Health
- New York, New York
Details
This activity is supported by an educational grant from Astellas and Seagen Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 103421GUBC-CTB